Ignite Creation Date:
2024-05-06 @ 7:08 AM
Last Modification Date:
2024-10-26 @ 11:45 AM
Study NCT ID:
NCT02474667
Status:
UNKNOWN
Last Update Posted:
2021-06-03
First Post:
2015-06-12
Brief Title:
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
Sponsor:
Angion Biomedica Corp
Organization:
Angion Biomedica Corp
Study Overview
Official Title:
A Multicenter Prospective Double-Blind Randomized Placebo-Controlled Phase 3 Study of ANG-3777 Formerly BB3 to Improve Graft Function and Reduce the Severity of Kidney Dysfunction or Delayed Graft Function Following Kidney Transplantation in Recipients of a Deceased Donor Kidney
Status:
UNKNOWN
Status Verified Date:
2021-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function DGF in recipients at high risk of DGF after receiving a deceased donor renal allograft
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None